Debate: Will chemotherapy continue to be standard treatment for symptomatic mCRPC in the era of novel agents? (for)
Debate: Will chemotherapy continue to be standard treatment for symptomatic mCRPC in the era of novel agents? (for)
Debate: Will chemotherapy continue to be standard treatment for symptomatic mCRPC in the era of novel agents? (against)
Lecture: Future strategies and targets for prostate cancer
WIN Symposium 2014: Breakthrough biomarker investigations and combination therapies
Work and history of the Kidney Cancer Association
Intratumour heterogeneity in renal and lung cancer
High levels of mutated p53 indicate metastatic phenotype
Phase II trial shows dacomitinib benefits a subgroup of patients with head and neck cancer
"Exciting" implications of bemacyclib study in the treatment of breast cancer
Impact of the liver environment upon the efficacy of induction therapy
Study identifies new strategy to overcome breast cancer resistance to HER2-targeted therapies
Benefits found for lung cancer patients with high levels of PD-L1 with MK-3475 treatment